The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1728
May 12, 2025
View Complete Issue         Table of Contents 2019 
Landiolol (Rapiblyk) for Short-Term Rate Control in Supraventricular Tachycardia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Landiolol (Rapiblyk) for Short-Term Rate Control in Supraventricular Tachycardia
May 12, 2025 (Issue: 1728)
The FDA has approved the intravenously administered beta1-adrenergic blocker landiolol (Rapiblyk – AOP) for short-term reduction of ventricular rate in adults with supraventricular tachycardia including atrial fibrillation and atrial flutter....more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Landiolol (Rapiblyk) for Short-Term Rate Control in Supraventricular Tachycardia
Article code: 1728b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.